tbuckley/cabot-search huggingface dataset:
Sugar-Sweetened Beverages and Risk of Liver Disease
Authors: Ibrahim Ayada, Jiajing Li, Qiuwei Pan
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16594: Impact of Anemia on Long-Term Clinical Outcome in Patients With Mildly Reduced Left Ventricular Systolic Function After Acute Myocardial Infarction
Authors: Jaeho Seung, Sang Hoon Shin, Chang Yong Shin, junghyuck lee, Do Young Kim, yeo reum kim, Hyun Ki Lee, Moon Kyung Jung, Kyung Hoon Roh, YONGHEE KIM, Jin-jin Kim, Byung-Hee Hwang, Kiyuk Chang
Journal: Circulation (2023)

Background: Anemia may confer a poor prognosis among patients with acute coronary syndrome. However, contemporary data are lacking on the prognostic importance of anemia in patients with mildly reduced left ventricular (LV) systolic function after acute myocardial infarction (AMI). Methods: AMI patients receiving percutaneous coronary intervention were consecutively enrolled from January 2004 to August 2014. A total of 2,172 patients with mild LV systolic dysfunction: LV ejection fraction 40 49% as measured by echocardiography, were divided according to the presence of anemia. Anemia was defined as a hemoglobin level &lt;14 g/dL in men and &lt;12 g/dL in women. All-cause mortality within a follow-up period was compared in groups of patients with and without anemia. Results: Median follow-up duration was 56.9 months (interquartile range 34.5 to 85.7 months). Patients with anemia were older, more likely to have diabetes and hypertension, but the two groups did not differ in sex and presence of dyslipidemia. The prescription rates of beta-blockers and angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists at discharge were similar in both groups, but those of potent P2Y12 inhibitors and statins were lower in patients with anemia. Patients with anemia had greater all-cause mortality (19.3% vs. 36.7%). Anemia was an independent predictor of all-cause mortality after adjusting confounding risk factors (hazard ratio: 1.301, confidence interval: 1.053-1.607, p=0.030). Conclusion: In patients with mildly reduced LV systolic function after AMI, anemia is associated with poorer outcome independently of coexisting risk factors.
Clinical Guidelines for Priapism—Reply
Authors: Richard J. Fantus, Andrew M. Davis, Robert E. Brannigan
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sugar-Sweetened Beverages and Risk of Liver Disease—Reply
Authors: Longgang Zhao, Xinyuan Zhang, Xuehong Zhang
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
O.R. 34
Authors: Isabel Cristina Legarda
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Osteoporosis and Fracture Risk Following Benign Hysterectomy Among Female Patients in Korea
Authors: Yong-Soo Seo, Jin-Sung Yuk
Journal: JAMA Network Open (2023)

IMPORTANCE Prior research about the association between hysterectomy and osteoporosis risk had limitations. OBJECTIVE To assess osteoporosis and fracture risk among female patients who underwent hysterectomy due to benign conditions. DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study, female patients aged 40 to 59 years with benign hysterectomy between 2003 and 2011 were selected from Korean National Health Insurance Data and matched by 1:1 propensity score with female patients who had health checkups and indicated that they had not had a hysterectomy. A Cox proportional hazard model was used to analyze osteoporosis and fracture risk, with participants monitored until December 31, 2020. Data analysis was performed from July 16, 2022, to January 12, 2023. EXPOSURES Hysterectomy with or without adnexal surgical procedure. MAIN OUTCOMES AND MEASURES The primary outcome was the risk of osteoporosis. Secondary outcomes included the risk of vertebral fracture, hip fracture, other fractures, and total fracture. RESULTS The study population included 25 910 patients; the median (IQR) age was 47 (44-50) years, and median (IQR) follow-up period was 10.9 (9.4-12.7) years. In the stratified-extended Cox proportional analysis, female patients who underwent hysterectomy without an adnexal surgical procedure were associated with a higher risk of osteoporosis within 7 years compared with female patients who did not undergo hysterectomy (hazard ratio [HR], 1.28 [95% CI, 1.19-1.37]); the analysis was divided into 7 years due to a violation of the Cox assumption, and the risk did not differ after 7 years (HR, 0.99 [95% CI, 0.93-1.06]). However, the hysterectomy group with an adnexal surgical procedure had an association with higher risk of osteoporosis compared with the nonhysterectomy group both within 7 years of study entry (HR, 1.56 [95% CI, 1.33-1.82]) and after 7 years (HR, 1.20 [95% CI, 1.04-1.40]). In the hysterectomy group without an adnexal surgical procedure, the risks of vertebral fracture, hip fracture, and total fracture were similar to those in the nonhysterectomy group. Similar trends were observed in the hysterectomy group with an adnexal surgical procedure. CONCLUSIONS AND RELEVANCE Hysterectomy without an adnexal surgical procedure was associated with an increased osteoporosis risk within 7 years, but not afterwards, compared with the nonhysterectomy group. Hysterectomy was not associated with vertebral and hip fractures.
Antiplatelet Therapy, Abdominal Aortic Aneurysm Progression, and Clinical Outcomes
Authors: Essa Hariri, Milad Matta, Habib Layoun, Osamah Badwan, Lorenzo Braghieri, A. Phillip Owens, Robert Burton, Rohan Bhandari, Doran Mix, John Bartholomew, David Schumick, Ayman Elbadawi, Samir Kapadia, Stanley L. Hazen, Lars G. Svensson, Scott J. Cameron
Journal: JAMA Network Open (2023)

Importance Preclinical studies suggest a potential role for aspirin in slowing abdominal aortic aneurysm (AAA) progression and preventing rupture. Evidence on the clinical benefit of aspirin in AAA from human studies is lacking. Objective To investigate the association of aspirin use with aneurysm progression and long-term clinical outcomes in patients with AAA. Design, Setting, and Participants This was a retrospective, single-center cohort study. Adult patients with at least 2 available vascular ultrasounds at the Cleveland Clinic were included, and patients with history of aneurysm repair, dissection, or rupture were excluded. All patients were followed up for 10 years. Data were analyzed from May 2022 to July 2023. Main Outcomes and Measures Clinical outcomes were time-to-first occurrence of all-cause mortality, major bleeding, or composite of dissection, rupture, and repair. Multivariable-adjusted Cox proportional-hazard regression was used to estimate hazard ratios (HR) for all-cause mortality, and subhazard ratios competing-risk regression using Fine and Gray proportional subhazards regression was used for major bleeding and composite outcome. Aneurysm progression was assessed by comparing the mean annualized change of aneurysm diameter using multivariable-adjusted linear regression and comparing the odds of having rapid progression (annual diameter change &amp;amp;gt;0.5 cm per year) using logistic regression. Results A total of 3435 patients (mean [SD] age 73.7 [9.0] years; 2672 male patients [77.5%]; 120 Asian, Hispanic, American Indian, or Pacific Islander patients [3.4%]; 255 Black patients [7.4%]; 3060 White patients [89.0%]; and median [IQR] follow-up, 4.9 [2.5-7.5] years) were included in the final analyses, of which 2150 (63%) were verified to be taking aspirin by prescription. Patients taking aspirin had a slower mean (SD) annualized change in aneurysm diameter (2.8 [3.0] vs 3.8 [4.2] mm per year; P = .001) and lower odds of having rapid aneurysm progression compared with patients not taking aspirin (adjusted odds ratio, 0.64; 95% CI, 0.49-0.89; P = .002). Aspirin use was not associated with risk of all-cause mortality (adjusted HR [aHR], 0.92; 95% CI, 0.79-1.07; P = .32), nor was aspirin use associated with major bleeding (aHR, 0.88; 95% CI, 0.76-1.03; P = .12), or composite outcome (aHR, 1.16; 95% CI, 0.93-1.45; P = .09) at 10 years. Conclusions In this retrospective study of a clinical cohort of 3435 patients with objectively measured changes in aortic aneurysm growth, aspirin use was significantly associated with slower progression of AAA with a favorable safety profile.
Abstract 15015: Clinical Outcomes of Patients With Heart Failure With Improved Ejection Fraction After Acute MI: A Multicenter Prospective Study From the COREA-AMI Registry
Authors: yeo reum kim, Sang Hoon Shin, Chang Yong Shin, junghyuck lee, Do Young Kim, Hyun Ki Lee, Kyung Hoon Roh, YONGHEE KIM, Jaeho Seung, Moon Kyung Jung, Kyung An Kim, Kwan Yong Lee, Byung-Hee Hwang, Kiyuk Chang
Journal: Circulation (2023)

Background: The 2021 Universal Definition of Heart Failure introduce a new classification, heart failure with improved ejection fraction (HFimpEF). As yet, little is known about the long-term clinical outcomes of patients with HFimpEF after acute myocardial infarction (AMI). Methods: From a multicenter, prospective cohort of AMI patients undergoing PCI, patients with an initial TTE at the time of PCI and at least one follow-up TTE 1 month to 2 years after the initial event were considered for analysis. HFimpEF was defined as initial left ventricular ejection fraction (LVEF)≤40% and at least one follow-up LVEF&gt;40% with an increase of ≥10% from baseline. Persistent HFrEF was defined as LVEF ≤40% without interval improvement. Patients with LVEF&gt;40% were defined as having preserved LVEF. The primary endpoint was all-cause mortality. Results: In total, 3038 patients with repeated TTE measurements were selected for initial analysis. 187 patients were identified as having HFimpEF, 190 patients had persistent HFrEF, 631 patients had HFmrEF, and 2030 patients had preserved EF. Kaplan-Meier analysis revealed that HFimpEF was associated with improved survival compared to chronic HFrEF, but inferior to preserved LVEF (log-rank p&lt;0.001). Even after multivariate Cox regression analysis was done to account for confounding variables, HFimpEF was associated with reduced mortality compared to persistent HFrEF (HR 0.49, 95% CI 0.31-0.78). Compared to patients with preserved LVEF, HFimpEF patients had a tendency toward higher mortality, but did not reach statistical significance (HR 1.18, 95% CI 0.80-1.76). Conclusion: HFimpEF is associated with decreased all-cause mortality compared to persistent HFrEF in patients with AMI. Figure 1. Kaplan-Meier Survival Analysis According to Changes in LVEF
Abstract 15023: Fractional Flow Reserve-Guided Complete Revascularization in AMI Patients With Angiographically Severe Non-Culprit Lesion: FRAME-AMI Substudy
Authors: Jaeho Seung, Sang Hoon Shin, Chang Yong Shin, junghyuck lee, Do Young Kim, yeo reum kim, Hyun Ki Lee, Kyung Hoon Roh, Moon Kyung Jung, YONGHEE KIM, Eunho Choo, Byung-Hee Hwang, Kiyuk Chang
Journal: Circulation (2023)

Background: The benefit of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) for non-culprit lesions with angiographically severe stenosis in patients with acute myocardial infarction (AMI) is unclear Objectives We evaluated the relationship between non-culprit lesion stenosis measured by quantitative coronary angiography (QCA) and the efficacy of FFR-guided PCI Methods: Severity of non-culprit lesion stenosis of 562 patients from FRAME-AMI (FFR vs. Angiography-Guided Strategy for Management of Non-Infarction Related Artery Stenosis in Patients with AMI) was measured using QCA in the core laboratory. The effect of FFR-guided versus angiography-guided PCI according to non-culprit lesion stenosis (QCA stenosis ≥70% or &lt;70%) on the primary end point (risk of death, MI or repeat revascularization) was analyzed Results: At a median follow-up of 3.5 years, the primary end point occurred in 14 patients of 181 patients with FFR-guided PCI and 31 of 197 patients with angiography-guided PCI among patient with QCA stenosis ≥70% (7.7% vs 15.7%; hazard ratio, 0.48; 95% confidence interval, 0.25 to 0.90; P=0.022), while occurred in 4 of 103 patients with FFR-guided PCI and 9 of 81 patients with angiography-guided PCI among those with QCA stenosis &lt; 70% (3.9% vs 11.1%, p=0.079). FFR-guided PCI was associated with the reduction of death and myocardial infarction in patients with QCA stenosis ≥70% (6.1% vs 13.7%, p=0.019) and those with QCA stenosis &lt; 70% (1.0% vs 9.9%, p=0.028) compare to angiography-guided PCI Conclusions: In patients with AMI and multivessel disease, patients with severe non-infarct related artery lesion was also benefited by FFR-guided PCI.
Percutaneous Coronary Intervention–Capable Facility Openings and Acute Myocardial Infarction Outcomes by Patient Race and Community Segregation
Authors: Renee Y. Hsia, Yu-Chu Shen
Journal: JAMA Network Open (2023)

This cohort study investigates differential changes in patient outcomes after percutaneous coronary intervention–capable facility openings by patient race and community segregation.
ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
Authors: Hang Xu, Yi-Fan Li, Xian-Yan-Ling Yi, Xiao-Nan Zheng, Yang Yang, Yan Wang, Da-Zhou Liao, Jia-Peng Zhang, Ping Tan, Xing-Yu Xiong, Xi Jin, Li-Na Gong, Shi Qiu, De-Hong Cao, Hong Li, Qiang Wei, Lu Yang, Jian-Zhong Ai
Journal: Military Medical Research (2023)

Abstract Background Cell metabolism plays a pivotal role in tumor progression, and targeting cancer metabolism might effectively kill cancer cells. We aimed to investigate the role of hexokinases in prostate cancer (PCa) and identify a crucial target for PCa treatment. Methods The Cancer Genome Atlas (TCGA) database, online tools and clinical samples were used to assess the expression and prognostic role of ADP-dependent glucokinase (ADPGK) in PCa. The effect of ADPGK expression on PCa cell malignant phenotypes was validated in vitro and in vivo. Quantitative proteomics, metabolomics, and extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) tests were performed to evaluate the impact of ADPGK on PCa metabolism. The underlying mechanisms were explored through ADPGK overexpression and knockdown, co-immunoprecipitation (Co-IP), ECAR analysis and cell counting kit-8 (CCK-8) assays. Results ADPGK was the only glucokinase that was both upregulated and predicted worse overall survival (OS) in prostate adenocarcinoma (PRAD). Clinical sample analysis demonstrated that ADPGK was markedly upregulated in PCa tissues vs. non-PCa tissues. High ADPGK expression indicates worse survival outcomes, and ADPGK serves as an independent factor of biochemical recurrence. In vitro and in vivo experiments showed that ADPGK overexpression promoted PCa cell proliferation and migration, and ADPGK inhibition suppressed malignant phenotypes. Metabolomics, proteomics, and ECAR and OCR tests revealed that ADPGK significantly accelerated glycolysis in PCa. Mechanistically, ADPGK binds aldolase C (ALDOC) to promote glycolysis via AMP-activated protein kinase (AMPK) phosphorylation. ALDOC was positively correlated with ADPGK, and high ALDOC expression was associated with worse survival outcomes in PCa. Conclusions In summary, ADPGK is a driving factor in PCa progression, and its high expression contributes to a poor prognosis in PCa patients. ADPGK accelerates PCa glycolysis and progression by activating ALDOC-AMPK signaling, suggesting that ADPGK might be an effective target and marker for PCa treatment and prognosis evaluation.
Abstract 15061: Long-Term Outcome of Stentless Coronary Intervention With Drug-Coated Balloon in Patients With High Bleeding Risk
Authors: Kohei Nagano, Tomonori Takahashi, Tetsuzo Wakatsuki, Bando Ryo, Robert Zheng, Yoshihiro Saijo, Muneyuki Kadota, Yutaka Kawabata, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Shusuke Yagi, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata
Journal: Circulation (2023)

Introduction: Conventional PCI with stenting in high bleeding risk (HBR) patients is associated withhigher all-cause mortality rates and bleeding complications. To minimize DAPT duration, stentlessPCI using drug-coated balloons (DCB) is increasingly favored. However, there is a lack ofcomprehensive long-term outcome data on stentless therapy in HBR patients within real-worldclinical practice. Research Questions: Do discernible disparities exist in the extended-term ramifications of stentless treatment utilizing DCB between patients classified as having HBR and those without in clinical practice? Methods: We incorporated patients who underwent stentless PCI employing DCB for de novo lesions at our medical facility from January 2015 to December 2021. Exclusion criteria encompassedpatients presenting with acute coronary syndromes. The primary outcome measure was defined as all-cause mortality, whereas the secondary outcome measure focused on bleeding events as per thedefined criteria of BARC bleeding grades 3 or 5. Patients were stratified into two cohorts based on the ARC-HBR criteria and subsequently subjected to comparative analysis utilizing Cox proportional hazards regression analysis. Results: A total of 392 patients were included, including a mean age of 70 ± 11 years and 46% male. Of these patients, 62% had HBR, and the procedure's success rate was 99.7%. Over a median follow-up period of 24 months, 29 patients (7.4%) experienced all-cause mortality. HBR patients showed significantly higher blood BNP levels compared to non-HBR patients (median [IQR]: 85pg/mL [36-226] vs. 27 pg/mL [15-49], p&lt;0.01). After adjusting for blood BNP levels, the hazard ratio for all-cause mortality in HBR patients was 4.06 [1.18-14.00], indicating a 4-fold higher risk compared to non-HBR patients (p=0.03). Among the cohort, 12 individuals (1.8%) experienced BARC grades 3 or 5 bleeding events, with a tendency towards a greater occurrence in the HBRpatient group (adjusted HR: 2.26 [0.46-11.20], p=0.32), although the difference was not significant. Conclusions: The findings further indicate that patients with HBR exhibit a propensity for inferior long-term outcomes relative to non-HBR patients in stentless treatment with DCB in the real world.